The administration of combined anti-estrogen and HER2-targeted therapies in HER2+/ER+ breast cancer has been demonstrated to improve overall response rate (ORR), clinical benefit rate (CBR) and progression-free survival (PFS) as compared to anti-estrogen alone [9–11]. This evidence concerns the gene ERBB2 and breast cancer.